Cabergoline and Breast enlargement - a phase IV clinical study of FDA data

Summary:

Breast enlargement is reported as a side effect among people who take Cabergoline (cabergoline), especially for people who are female, 30-39 old, also take Premarin, and have Acromegaly.

The phase IV clinical study analyzes which people have Breast enlargement when taking Cabergoline. It is created by eHealthMe based on reports of 5,946 people who have side effects when taking Cabergoline from the FDA, and is updated regularly.

What is Cabergoline?

Cabergoline has active ingredients of cabergoline. It is often used in prolactinoma. eHealthMe is studying from 6,257 Cabergoline users. Check the latest studies of Cabergoline.

What is Breast enlargement?

Breast enlargement is found to be associated with 339 drugs and 540 conditions by eHealthMe. Check the latest studies of Breast enlargement.

On Jul, 14, 2026

5,946 people reported to have side effects when taking Cabergoline.
Among them, 18 people (0.3%) have Breast enlargement.

Could Cabergoline cause Breast enlargement?

Among these 18 people:

What is the gender of people who have Breast enlargement when taking Cabergoline? *

female: 88.89 %
male: 11.11 %

What is the age of people who have Breast enlargement when taking Cabergoline? *

What are other drugs people take besides Cabergoline? *

What are other side effects people have besides Breast enlargement? *

Fatigue (feeling of tiredness): 16 people, 88.89%
Weight Increased: 12 people, 66.67%
Pain: 12 people, 66.67%
Joint Pain: 12 people, 66.67%
Injection Site Pain: 11 people, 61.11%
Body Height Decreased: 8 people, 44.44%
Malaise (a feeling of general discomfort or uneasiness): 8 people, 44.44%
Drowsiness: 8 people, 44.44%
Injection Site Nodule (small swelling or aggregation of cells in the body, esp. an abnormal one at injection site): 8 people, 44.44%
Injection Site Infection: 8 people, 44.44%

What are the existing conditions these people have? *

Acromegaly (body produces too much growth hormone, leading to excess growth of body tissues): 12 people, 66.67%
Infertility: 4 people, 22.22%
Breast Pain: 4 people, 22.22%
Maternal Therapy To Enhance Foetal Lung Maturity: 2 people, 11.11%
Hormone Level Abnormal: 2 people, 11.11%
High Blood Pressure: 2 people, 11.11%
Diabetes: 2 people, 11.11%
Blood Oestrogen Decreased: 2 people, 11.11%
Restless Leg Syndrome (a powerful urge to move your legs): 1 person, 5.56%
Glaucoma (increased fluid pressure in the eye with vision loss): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Cabergoline and have Breast enlargement?

- Check whether Breast enlargement is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cabergoline:

Cabergoline (6,257 reports)

Browse all side effects of Cabergoline:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Breast enlargement:

Breast enlargement (339 drugs)

Browse all the conditions that are associated with Breast enlargement:

Breast enlargement (540 conditions)

Related publications that referenced our studies

Gürbüz F, Ya?c?-Küpeli B, K?r Y, Yüksel B, Zorludemir S, Gürbüz BB, Küpeli S, "The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma", Journal of Pediatric Endocrinology and Metabolism, 2014 Jan .
Harris YT, Harris AZ, "Cabergoline associated with first episode mania", Psychosomatics, 2012 Jan .
Gürbüz F, Ya?c?-Küpeli B, K?r Y, Yüksel B, Zorludemir S, Gürbüz BB, Küpeli S, "The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma", Journal of Pediatric Endocrinology and Metabolism, 2014 Jan .
Harris YT, Harris AZ, "Cabergoline associated with first episode mania", Psychosomatics, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on cabergoline (the active ingredients of Cabergoline) and Cabergoline (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.